FDA Grants Priority Review to Genentech’s Gazyva for Rare Kidney Disease
Event summary
- Genentech's Gazyva (obinutuzumab) receives FDA priority review for primary membranous nephropathy (pMN), a rare kidney disease with no approved treatments.
- Phase III MAJESTY study shows Gazyva achieved 36.9% complete remission vs. 5.7% with tacrolimus at two years.
- FDA decision expected by November 2026, following Breakthrough Therapy Designation granted in April 2026.
The big picture
Genentech’s Gazyva is positioning itself as a potential cornerstone therapy in immune-mediated kidney diseases, following positive Phase III data and regulatory momentum. The priority review underscores the unmet need in pMN, where current treatments are limited to off-label immunosuppressants. Success here could further solidify Genentech’s leadership in immunology, complementing its existing approvals in lupus nephritis.
What we're watching
- Regulatory Momentum
- Whether the FDA approval will expand Gazyva’s use beyond lupus nephritis into other immune-mediated kidney diseases.
- Commercial Strategy
- How Genentech positions Gazyva in a market with limited therapeutic options for pMN.
- Pipeline Expansion
- The pace at which Genentech advances other immunology assets, including Lunsumio (mosunetuzumab) for SLE.
Related topics